Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder
Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder
复制标题
DOI：
10.1016/j.jpsychires.2008.10.015
复制
发表时间：
2009-06-01
影响因子：
4.8
通讯作者：
Herrera-Abarca, Jorge E.
中科院分区：
文献类型：
--
作者：
Herrera-Guzman, Ixchel;Gudayol-Ferre, Esteve;Herrera-Abarca, Jorge E.
重度抑郁症（MOD）患者通常会出现情景记忆、工作记忆、心理加工速度和运动反应等认知功能的改变。不同的研究表明，不同的抗抑郁药可以改善MDD患者的认知功能。本研究的目的是研究多巴胺能再摄取抑制剂（SSRIs）和多巴胺能-去甲肾上腺素能再摄取抑制剂（SNRIs）对改善MDD患者记忆任务表现和心理加工速度的作用。73例符合重度抑郁症标准的受试者采用汉密尔顿抑郁量表和神经心理学成套测验进行评估。受试者接受艾司西酞普兰（n = 36）或度洛昔单抗（n = 37）治疗24周。在试验结束时，再次使用治疗前使用的相同神经心理成套测试对受试者进行评估。这两种治疗方法都能显著改善情景记忆，并在较小程度上改善工作记忆、心理处理速度和运动表现。我们的研究结果表明，认知部分独立于临床症状的改善。治疗24周后，两组在HAM-D-17中均达到缓解率，但SNRI在改善情景记忆和工作记忆方面上级优于SSRI。我们的工作表明，SNRI优于SSRI在情节记忆改善临床相关。(C)2008年由Elsevier Ltd.出版
Patients with major depressive disorder (MOD) usually suffer from altered cognitive functions of episodic memory, working memory, mental processing speed and motor response. Diverse studies suggest that different antidepressant agents may improve cognitive functions in patients with MDD. The aim of this work is to study the effects of serotonergic reuptake inhibitors (SSRIs) and serotonergic-noradrenergic reuptake inhibitors (SNRIs) treatments to improve the performance on memory tasks and mental processing speed in MDD. Seventy-three subjects meeting criteria for major depressive disorder were assessed with the Hamilton depression rating scale and a neuropsychological battery. The subjects were medicated with escitalopram (n = 36) or duloxetine (n = 37) for 24 weeks. At the end of the trial, the subjects were assessed again with the same neuropsychological battery used prior to the treatment. Both treatments improved importantly the episodic memory and to a lesser extent, working memory, mental processing speed and motor performance. Our results suggest that cognition is partially independent from improvement in clinical symptoms. Both groups achieved remission rates in the HAM-D-17 after 24 weeks of treatment, but SNRI was superior to SSRI at improving episodic and working memory. Our work indicates that the superiority of SNRI over the SSRI at episodic memory improvement is clinically relevant. (C) 2008 Published by Elsevier Ltd.